Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients-Reference-Cited by-同舟云学术

Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients

Published:2017-12-29 Issue:4 Volume:78 Page:250-256
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Fan Liancheng¹,Wang Rui²,Chi Chenfei¹,Cai Wen¹,Zhang Yong¹,Qian Hongyang¹,Shao Xiaoguang¹,Wang Yanqing¹,Xu Fan¹,Pan Jiahua¹,Zhu Yinjie¹,Shangguan Xun¹,Zhou Lixin¹,Dong Baijun¹,Xue Wei¹^ORCID

Affiliation:

1. Department of Urology, Renji Hospital, School of Medicine; Shanghai Jiao Tong University; Shanghai China

2. Department of Ultrasound in Medicine, Shanghai Institute of Ultrasound in Medicine; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Xuhui District; Shanghai China

Funder

Science and Technology Commission of Shanghai Municipality

Shanghai Jiao Tong University School of Medicine

National Natural Science Foundation of China

Shanghai Municipal Education Commission

Shanghai Municipal Commission of Health and Family Planning

The Joint Research Foundation for Innovative Medical Technology of Shanghai Shenkang Hospital Development Center

Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai

Publisher

Wiley

Subject

Urology,Oncology